Androgen receptor coactivator p120 subtype β is highly expressed in prostate cancer.

Abstract

PURPOSE:

The β form of p120 is reported to be a strong coactivator of the androgen receptor. We investigated the gene expression profiles of the α and β forms of p120 in prostate cancer cell lines, benign prostatic hyperplasia (BPH), nontreated prostate cancer (NTPC), and prostate cancer after androgen deprivation therapy (PCA-ADT).

METHODS:

We obtained 154 prostate needle biopsy specimens (81 in BPH, 51 in NTPC, and 22 in PCA-ADT). Levels of p120α and β expression were determined by multiplex real-time polymerase chain reaction.

RESULTS:

Prostate cancer cell lines, LNCaP, PC-3, DU-145, and LNCaP-LA, which is a derivative of LNCaP under androgen deprivation, expressed both p120α and p120β. p120α expression levels were significantly higher than those of p120β in all cell lines examined. In human prostate tissues, p120α expression was significantly higher than that of p120β in BPH and NTPC. p120α expression in BPH was significantly higher than in other groups. In contrast, p120β expression was significantly higher in NTPC and PCA-ADT than in BPH. Expression of the two forms of p120 was not correlated with age, prostate-specific antigen, or Gleason score.

CONCLUSIONS:

The expression profiles of p120α and p120β significantly differ in cancerous and benign prostatic tissues.

• Authors: Kazumichi Muramatsu, Hiroshi Matsui, Yoshitaka Sekine, Hidekazu Koike, Yasuhiro Shibata, Kazuto Ito, Kazuhiro Suzuki
• Journal: Prostate international (Prostate Int) Vol. 1 Issue 1 Pg. 10-5 ( 2013) ISSN: 2287-8882 [Print] Korea (South)
• PMID: 24223396 (Publication Type: Journal Article)